DDInter948 DDInter1294
Human interferon beta (165 residues), cysteine 17 is substituted with serine. Produced in E. coli, no carbohydrates, MW=18.5kD
Nilutamide is an antineoplastic hormonal agent primarily used in the treatment of prostate cancer. Nilutamide is a pure, nonsteroidal anti-androgen with affinity for androgen receptors (but not for progestogen, estrogen, or glucocorticoid receptors). Consequently, Nilutamide blocks the action of androgens of adrenal and testicular origin that stimulate the growth of normal and malignant prostatic tissue. Prostate cancer is mostly androgen-dependent and can be treated with surgical or chemical castration. To date, antiandrogen monotherapy has not consistently been shown to be equivalent to castration.
Nilutamide {u} (Compound) resembles {v} (Compound) Flutamide
Nilutamide {u} (Compound) treats {v} (Disease) prostate cancer
Nilutamide {u} (Compound) binds {v} (Gene) POR
Nilutamide {u} (Compound) is included by {v} (Pharmacologic Class) Androgen Receptor Antagonists
Nilutamide {u} (Compound) causes {v} (Side Effect) Ill-defined disorder
Nilutamide (Compound) resembles Flutamide (Compound)
Nilutamide (Compound) treats prostate cancer (Disease)
Nilutamide (Compound) binds POR (Gene)
Nilutamide (Compound) is included by Androgen Receptor Antagonists (Pharmacologic Class)
Nilutamide (Compound) causes Ill-defined disorder (Side Effect)